“… also strengthen Cytodyn's case against Amarex.”

Good point. I’m concerned that the aggregated safety data being essentially useless, that the holds won’t be lifted quickly. That’d be a catch 22 bc with holds on, how can you re-do or start new trials in order to properly aggregate safety data.